Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatmentresistant depression

Dana L. McMakin; Thomas M. Olino; Giovanna Porta; Laura J. Dietz; Graham Emslie; Gregory Clarke; Karen Dineen Wagner; Joan R. Asarnow; Neal D. Ryan; Boris Birmaher; Wael Shamseddeen; Taryn Mayes; Betsy Kennard; Anthony Spirito; Martin Keller; Frances L. Lynch; John F. Dickerson; David A. Brent

doi:10.1016/j.jaac.2012.01.011

Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatmentresistant depression

Dana L. McMakin, Thomas M. Olino, Giovanna Porta, Laura J. Dietz, Graham Emslie, Gregory Clarke, Karen Dineen Wagner, Joan R. Asarnow, Neal D. Ryan, Boris Birmaher, Wael Shamseddeen, Taryn Mayes, Betsy Kennard, Anthony Spirito, Martin Keller, Frances L. Lynch, John F. Dickerson, David A. Brent

Research output: Contribution to journal › Article › peer-review

306 Scopus citations

Abstract

Objective: To identify symptom dimensions of depression that predict recovery among selective serotonin reuptake inhibitor (SSRI) treatmentresistant adolescents undergoing second-step treatment. Method: The Treatment of Resistant Depression in Adolescents (TORDIA) trial included 334 SSRI treatmentresistant youth randomized to a medication switch, or a medication switch plus CBT. This study examined five established symptom dimensions (Child Depression Rating ScaleRevised) at baseline as they predicted recovery over 24 weeks of acute and continuation treatment. The two indices of recovery that were evaluated were time to remission and number of depression-free days. Results: Multivariate analyses examining all five depression symptom dimensions simultaneously indicated that anhedonia was the only dimension to predict a longer time to remission, and also the only dimension to predict fewer depression-free days. In addition, when anhedonia and CDRS-total score were evaluated simultaneously, anhedonia continued to uniquely predict longer time to remission and fewer depression-free days. Conclusions: Anhedonia may represent an important negative prognostic indicator among treatment-resistant depressed adolescents. Further research is needed to elucidate neurobehavioral underpinnings of anhedonia, and to test treatments that target anhedonia in the context of overall treatment of depression. Clinical trial registration informationTreatment of SSRI-Resistant Depression in Adolescents (TORDIA); http://www.clinicaltrials.gov; NCT00018902.

Original language	English (US)
Pages (from-to)	404-411
Number of pages	8
Journal	Journal of the American Academy of Child and Adolescent Psychiatry
Volume	51
Issue number	4
DOIs	https://doi.org/10.1016/j.jaac.2012.01.011
State	Published - Apr 2012

Keywords

adolescence
clinical trial
cognitive-behavioral therapy
depression
treatment-resistant

ASJC Scopus subject areas

Developmental and Educational Psychology
Psychiatry and Mental health

Access to Document

10.1016/j.jaac.2012.01.011

Cite this

McMakin, D. L., Olino, T. M., Porta, G., Dietz, L. J., Emslie, G., Clarke, G., Wagner, K. D., Asarnow, J. R., Ryan, N. D., Birmaher, B., Shamseddeen, W., Mayes, T., Kennard, B., Spirito, A., Keller, M., Lynch, F. L., Dickerson, J. F., & Brent, D. A. (2012). Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatmentresistant depression. Journal of the American Academy of Child and Adolescent Psychiatry, 51(4), 404-411. https://doi.org/10.1016/j.jaac.2012.01.011

McMakin, DL, Olino, TM, Porta, G, Dietz, LJ, Emslie, G, Clarke, G, Wagner, KD, Asarnow, JR, Ryan, ND, Birmaher, B, Shamseddeen, W, Mayes, T, Kennard, B, Spirito, A, Keller, M, Lynch, FL, Dickerson, JF & Brent, DA 2012, 'Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatmentresistant depression', Journal of the American Academy of Child and Adolescent Psychiatry, vol. 51, no. 4, pp. 404-411. https://doi.org/10.1016/j.jaac.2012.01.011

@article{5791189a78b645a79549f3463b089f72,

title = "Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatmentresistant depression",

abstract = "Objective: To identify symptom dimensions of depression that predict recovery among selective serotonin reuptake inhibitor (SSRI) treatmentresistant adolescents undergoing second-step treatment. Method: The Treatment of Resistant Depression in Adolescents (TORDIA) trial included 334 SSRI treatmentresistant youth randomized to a medication switch, or a medication switch plus CBT. This study examined five established symptom dimensions (Child Depression Rating ScaleRevised) at baseline as they predicted recovery over 24 weeks of acute and continuation treatment. The two indices of recovery that were evaluated were time to remission and number of depression-free days. Results: Multivariate analyses examining all five depression symptom dimensions simultaneously indicated that anhedonia was the only dimension to predict a longer time to remission, and also the only dimension to predict fewer depression-free days. In addition, when anhedonia and CDRS-total score were evaluated simultaneously, anhedonia continued to uniquely predict longer time to remission and fewer depression-free days. Conclusions: Anhedonia may represent an important negative prognostic indicator among treatment-resistant depressed adolescents. Further research is needed to elucidate neurobehavioral underpinnings of anhedonia, and to test treatments that target anhedonia in the context of overall treatment of depression. Clinical trial registration informationTreatment of SSRI-Resistant Depression in Adolescents (TORDIA); http://www.clinicaltrials.gov; NCT00018902.",

keywords = "adolescence, clinical trial, cognitive-behavioral therapy, depression, treatment-resistant",

author = "McMakin, {Dana L.} and Olino, {Thomas M.} and Giovanna Porta and Dietz, {Laura J.} and Graham Emslie and Gregory Clarke and Wagner, {Karen Dineen} and Asarnow, {Joan R.} and Ryan, {Neal D.} and Boris Birmaher and Wael Shamseddeen and Taryn Mayes and Betsy Kennard and Anthony Spirito and Martin Keller and Lynch, {Frances L.} and Dickerson, {John F.} and Brent, {David A.}",

year = "2012",

month = apr,

doi = "10.1016/j.jaac.2012.01.011",

language = "English (US)",

volume = "51",

pages = "404--411",

journal = "Journal of the American Academy of Child and Adolescent Psychiatry",

issn = "0890-8567",

publisher = "Elsevier Limited",

number = "4",

}

TY - JOUR

T1 - Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatmentresistant depression

AU - McMakin, Dana L.

AU - Olino, Thomas M.

AU - Porta, Giovanna

AU - Dietz, Laura J.

AU - Emslie, Graham

AU - Clarke, Gregory

AU - Wagner, Karen Dineen

AU - Asarnow, Joan R.

AU - Ryan, Neal D.

AU - Birmaher, Boris

AU - Shamseddeen, Wael

AU - Mayes, Taryn

AU - Kennard, Betsy

AU - Spirito, Anthony

AU - Keller, Martin

AU - Lynch, Frances L.

AU - Dickerson, John F.

AU - Brent, David A.

PY - 2012/4

Y1 - 2012/4

N2 - Objective: To identify symptom dimensions of depression that predict recovery among selective serotonin reuptake inhibitor (SSRI) treatmentresistant adolescents undergoing second-step treatment. Method: The Treatment of Resistant Depression in Adolescents (TORDIA) trial included 334 SSRI treatmentresistant youth randomized to a medication switch, or a medication switch plus CBT. This study examined five established symptom dimensions (Child Depression Rating ScaleRevised) at baseline as they predicted recovery over 24 weeks of acute and continuation treatment. The two indices of recovery that were evaluated were time to remission and number of depression-free days. Results: Multivariate analyses examining all five depression symptom dimensions simultaneously indicated that anhedonia was the only dimension to predict a longer time to remission, and also the only dimension to predict fewer depression-free days. In addition, when anhedonia and CDRS-total score were evaluated simultaneously, anhedonia continued to uniquely predict longer time to remission and fewer depression-free days. Conclusions: Anhedonia may represent an important negative prognostic indicator among treatment-resistant depressed adolescents. Further research is needed to elucidate neurobehavioral underpinnings of anhedonia, and to test treatments that target anhedonia in the context of overall treatment of depression. Clinical trial registration informationTreatment of SSRI-Resistant Depression in Adolescents (TORDIA); http://www.clinicaltrials.gov; NCT00018902.

AB - Objective: To identify symptom dimensions of depression that predict recovery among selective serotonin reuptake inhibitor (SSRI) treatmentresistant adolescents undergoing second-step treatment. Method: The Treatment of Resistant Depression in Adolescents (TORDIA) trial included 334 SSRI treatmentresistant youth randomized to a medication switch, or a medication switch plus CBT. This study examined five established symptom dimensions (Child Depression Rating ScaleRevised) at baseline as they predicted recovery over 24 weeks of acute and continuation treatment. The two indices of recovery that were evaluated were time to remission and number of depression-free days. Results: Multivariate analyses examining all five depression symptom dimensions simultaneously indicated that anhedonia was the only dimension to predict a longer time to remission, and also the only dimension to predict fewer depression-free days. In addition, when anhedonia and CDRS-total score were evaluated simultaneously, anhedonia continued to uniquely predict longer time to remission and fewer depression-free days. Conclusions: Anhedonia may represent an important negative prognostic indicator among treatment-resistant depressed adolescents. Further research is needed to elucidate neurobehavioral underpinnings of anhedonia, and to test treatments that target anhedonia in the context of overall treatment of depression. Clinical trial registration informationTreatment of SSRI-Resistant Depression in Adolescents (TORDIA); http://www.clinicaltrials.gov; NCT00018902.

KW - adolescence

KW - clinical trial

KW - cognitive-behavioral therapy

KW - depression

KW - treatment-resistant

UR - http://www.scopus.com/inward/record.url?scp=84859086857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859086857&partnerID=8YFLogxK

U2 - 10.1016/j.jaac.2012.01.011

DO - 10.1016/j.jaac.2012.01.011

M3 - Article

C2 - 22449646

AN - SCOPUS:84859086857

SN - 0890-8567

VL - 51

SP - 404

EP - 411

JO - Journal of the American Academy of Child and Adolescent Psychiatry

JF - Journal of the American Academy of Child and Adolescent Psychiatry

IS - 4

ER -

Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatmentresistant depression

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this